Feltl & Co Upgrades Biocept (BIOC) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 rises; Apple and Palantir set to report results
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts BIOC Hot Sheet
Price: $0.43 --0%
Rating Summary:
5 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 21 | Down: 24 | New: 16
Rating Summary:
5 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 21 | Down: 24 | New: 16
Join SI Premium – FREE
Feltl & Co upgraded Biocept (NASDAQ: BIOC) from Hold to Buy with a price target of $1.55.
For an analyst ratings summary and ratings history on Biocept click here. For more ratings news on Biocept click here.
Shares of Biocept closed at $0.55 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Upgrades Lumentum (LITE) to Strong Buy, 'Overreaction to Marvell Offer'
- Fox Advisors Upgrades Plexus (PLXS) to Overweight
- Bernstein SocGen Group Upgrades Nippon Life India Asset Management Ltd (NAM:IN) to Outperform
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
